Skip to main content

Table 2 Outcome measures on D1 and D84 (Mean ± SEM)

From: Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes

  Placebo Group (n = 11) MMPI Group (n = 9)
Measures Control D1 D84 D1 D84
CRP 1.9 ± 0.8 5.9 ± 1.8* 6.2 ± 1.8* 7.4 ± 3.3* 2.3 ± 0.4†
MPO 68.8 ± 6.6 88.6 ± 6.0* 94.5 ± 11.3* 110.2 ± 15.3* 91.6 ± 13.6†
SBP (mmHg) 115.7 ± 19.6 127.7 ± 5.7 133.4 ± 4.8 136.2 ± 6.5 137.5 ± 5.8
DBP (mmHg) 72.0 ± 10.5 77.0 ± 10.1 77.8 ± 11 77.8 ± 8.0 77.4 ± 11.2
TC (mg/dL) 177.5 ± 28.0 178.8 ± 13 152.2 ± 6 177.9 ± 14 165.1 ± 10
HDL (mg/dL) 54.0 ± 15.2 40.5 ± 3.2** 36.58 ± 3.0** 38.44 ± 2.6** 38.44 ± 3.2**
LDL (mg/dL) 106.7 ± 22.2 99.6 ± 12 82 ± 7 86 ± 9 86.4 ± 8.8
TG (mg/dL) 84.4 ± 39.0 209.1 ± 30** 191.5 ± 36** 235.9 ± 48** 188.6 ± 37**
AST (IU/L) 22.8 ± 7.7 30.8 ± 4.1 33.0 ± 6.1 24.4 ± 2.9 20.1 ± 1.4
Creatinine (mg/dL) 0.9 ± 0.2 0.83 ± 0.05 0.83 ± 0.07 0.91 ± 0.05 0.92 ± 0.06
Fasting glucose (mmol/L) 5.1 ± 1.2 9.4 ± 0.5** 8.8 ± 0.6** 8.0 ± 0.7** 8.0 ± 1.0**
A1C (%) 5.4 ± 0.2 8.6 ± 0.4 8.0 ± 0.3 8.3 ± 0.6 7.8 ± 0.4
AUCi 0.25 ± 0.07 0.57 ± 0.16 0.57 ± 0.13* 0.89 ± 0.31* 0.71 ± 0.29
HOMA-IS 53.4 ± 7.6 135.3 ± 32.7 164 ± 46.8 244.9 ± 98.5 433.1 ± 272.1
HOMA-IR 1.06 ± 0.1 21 ± 5.1 26 ± 9.8 14.3 ± 4.7 23.0 ± 11.1
ΔI30–0/ΔG30–0 98 ± 17.5 37.3 ± 51.1 54.3 ± 30 73.7 ± 35.9 16.6 ± 20.1†
Global MMP (uM 5-FAM/h-ug protein) 47.2 ± 3.2 43.8 ± 4 56.6 ± 10.1 56.8 ± 13.3 59.7 ± 4.3
IL-1β (pg/ml) 0.15 ± 0.06 0.14 ± 0.05 0.13 ± 0.04 0.27 ± 0.15 0.46 ± 0.22
IL-2 (pg/ml) 1.8 ± 0.6 1.1 ± 0.4 0.9 ± 0.3 0.7 ± 0.3 1.1 ± 0.4
IL-4 (pg/ml) 10.0 ± 2.5 7.3 ± 2.1 9.9 ± 4.5 9.8 ± 4.2 7.4 ± 2.3
IL-6 (pg/ml) 6.9 ± 1.5 5.3 ± 1.9 8.4 ± 3.5 10.9 ± 4.3 12.9 ± 5.4
IL-8 (pg/ml) 2.4 ± 0.4 2.8 ± 0.5 3.2 ± 0.5 4.8 ± 0.9 5.8 ± 1.0
IL-10 (pg/ml) 16.6 ± 3.8 15.1 ± 3.5 11.3 ± 3.0† 16.4 ± 5.2 16.8 ± 3.8
TNF-α (pg/ml) 4.7 ± 0.6 4.4 ± 0.4 4.4 ± 0.7 6.6 ± 1.3 5.8 ± 1.1
  1. *P < 0.05 versus control, **P < 0.01 versus control, †P < 0.05 vs. D1.